<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01892423</url>
  </required_header>
  <id_info>
    <org_study_id>GLI.04SPR.US10044</org_study_id>
    <nct_id>NCT01892423</nct_id>
  </id_info>
  <brief_title>Repeat Insult Patch Test for Daily Advance Cetaphil Moisturizing Lotion</brief_title>
  <official_title>Daily Advance Cetaphil Moisturizing Lotion: Human Repeat Insult Patch Test</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma Laboratories, L.P.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma Laboratories, L.P.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Human repeat insult patch test to assess the potential for Cetaphil Moisturizing Lotion Daily&#xD;
      Advance to induce sensitization to the skin&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Irritation responses</measure>
    <time_frame>average of 5 weeks</time_frame>
    <description>all patients will be assessed at 14 visits for redness (erythema), spreading, weeping, papules, vesicles, and bullae at application site</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">146</enrollment>
  <condition>Skin Irritation</condition>
  <arm_group>
    <arm_group_label>Cetaphil Moisturizing Lotion Daily Advance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject had Cetaphil Moisturizing Lotion Daily Advance applied</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cetaphil Moisturizing Lotion Daily Advance</intervention_name>
    <arm_group_label>Cetaphil Moisturizing Lotion Daily Advance</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-65 years&#xD;
&#xD;
          -  Good health&#xD;
&#xD;
          -  willingness to cooperate and participate&#xD;
&#xD;
          -  willingness to avoid topical products at test sites&#xD;
&#xD;
          -  willingness to avoid direct sun exposure to test sites&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals with active psoriasis or eczema&#xD;
&#xD;
          -  individuals with sunburn, acne, abrasions, scar tissue, or tattoos on test sites, or&#xD;
             disease of skin that might interfere&#xD;
&#xD;
          -  individuals who have had a mastectomy with axillary nodes were removed&#xD;
&#xD;
          -  individuals receiving anticancer, immunosuppressive treatments or medications, or&#xD;
             radiation&#xD;
&#xD;
          -  pregnant, nursing, or planned to become pregnant&#xD;
&#xD;
          -  use of topical steroids or drugs at test sites&#xD;
&#xD;
          -  active or untreated skin cancer&#xD;
&#xD;
          -  active hepatitis&#xD;
&#xD;
          -  current routine or frequent use of high doses of anti-inflammatory drugs&#xD;
&#xD;
          -  individuals who have had les than two week rest period since completion of previous&#xD;
             patch testing on upper back or upper arms&#xD;
&#xD;
          -  individuals with uncontrolled metabolic diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James H Herndon, MD, FAAD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Thomas J Stephens and Associates Inc</name>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <zip>75006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>June 26, 2013</study_first_submitted>
  <study_first_submitted_qc>July 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2013</study_first_posted>
  <last_update_submitted>July 1, 2013</last_update_submitted>
  <last_update_submitted_qc>July 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

